Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases

•Aggressive angiomyxoma is a rare mesenchymal myxoid neoplasm in women at reproductive age.•The main treatment is surgery, but local recurrence rate is high.•Careful preoperative evaluation and long-term follow-up are important. Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterize...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of obstetrics & gynecology and reproductive biology 2024-07, Vol.298, p.165-170
Hauptverfasser: Qu, Hong, Liu, Na, Liang, Huamao, Wang, Ying, Zhuang, Huiyu, Li, Hua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 170
container_issue
container_start_page 165
container_title European journal of obstetrics & gynecology and reproductive biology
container_volume 298
creator Qu, Hong
Liu, Na
Liang, Huamao
Wang, Ying
Zhuang, Huiyu
Li, Hua
description •Aggressive angiomyxoma is a rare mesenchymal myxoid neoplasm in women at reproductive age.•The main treatment is surgery, but local recurrence rate is high.•Careful preoperative evaluation and long-term follow-up are important. Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterized by a high recurrence rate, usually observed in the lower genital tract of women during their reproductive age. Seventeen cases of aggressive angiomyxoma confirmed by pathology from January 2007 to December 2021 in Beijing Chao-yang Hospital were included. We collected clinical data and summarized the clinical and immunohistochemical features. All seventeen included patients were females, aged between 23 and 57 years (mean, 37.7 years; median, 42 years). Fourteen patients were newly diagnosed and three were recurrent. The tumors were located in vulva (58.8 %), vagina (23.5 %), buttock (11.8 %), and cervix (5.9 %). The tumors size were 2 to 15 cm in greatest dimension (mean 8 ± 4.4 cm, median 6 cm). Follow-up data was available for nine patients, which ranged from 25 to 124 months (mean, 82 months; median, 80 months). At the end of follow-up, no other recurrence or metastasis was reported. Immunohistochemical analysis showed immunoreactive for estrogen (10/11) and progesterone (8/11) receptor, desmin (6/8), smooth muscle actin (4/10), and vimentin (4/4), S-100 (1/8) and CD34 (1/7). The Ki67 level was less than 5 % in five cases. AAM is a hormone-sensitive, distinct rare mesenchymal neoplasm with high incidence of local recurrence. Surgery is the preferred treatment, with complete resection being an essential prerequisite for minimizing the risk of recurrence.
doi_str_mv 10.1016/j.ejogrb.2024.05.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3057075437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0301211524002392</els_id><sourcerecordid>3057075437</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-f8de91028425c52a1c18f71fc8e75faafe422600b0bfc229d331b3e9a45d2013</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gcgevew6STbNrgdBil9QEKSeQzY7KSm73ZrsFvvvTWn16FxmYN53Ph5CrilkFOj0bpXhqlv6KmPA8gxEBpSdkDEtJEvlVOSnZAwcaMooFSNyEcIKYnBenpMRL-SUlYKNyefjcukxBLfFRK-Xrmt3312rk84mFlvdYLLBZutCbNax9G6NQ3uffGDvu7BB0--NoR_q3d5CZWJ0wHBJzqxuAl4d84Qsnp8Ws9d0_v7yNnucp4YL2ae2qLGkwIqcCSOYpoYWVlJrCpTCam0xZ2wKUEFlDWNlzTmtOJY6FzUDyifk9jB247uvAUOvWhcMNo1eYzcExUFIkCLnMkrzg9TEu4NHqzbetdrvFAW156lW6sBT7XkqECryjLab44aharH-M_0CjIKHgwDjm1uHXgXjcG2wdj7SUXXn_t_wA6MMiIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3057075437</pqid></control><display><type>article</type><title>Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases</title><source>Elsevier ScienceDirect Journals</source><creator>Qu, Hong ; Liu, Na ; Liang, Huamao ; Wang, Ying ; Zhuang, Huiyu ; Li, Hua</creator><creatorcontrib>Qu, Hong ; Liu, Na ; Liang, Huamao ; Wang, Ying ; Zhuang, Huiyu ; Li, Hua</creatorcontrib><description>•Aggressive angiomyxoma is a rare mesenchymal myxoid neoplasm in women at reproductive age.•The main treatment is surgery, but local recurrence rate is high.•Careful preoperative evaluation and long-term follow-up are important. Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterized by a high recurrence rate, usually observed in the lower genital tract of women during their reproductive age. Seventeen cases of aggressive angiomyxoma confirmed by pathology from January 2007 to December 2021 in Beijing Chao-yang Hospital were included. We collected clinical data and summarized the clinical and immunohistochemical features. All seventeen included patients were females, aged between 23 and 57 years (mean, 37.7 years; median, 42 years). Fourteen patients were newly diagnosed and three were recurrent. The tumors were located in vulva (58.8 %), vagina (23.5 %), buttock (11.8 %), and cervix (5.9 %). The tumors size were 2 to 15 cm in greatest dimension (mean 8 ± 4.4 cm, median 6 cm). Follow-up data was available for nine patients, which ranged from 25 to 124 months (mean, 82 months; median, 80 months). At the end of follow-up, no other recurrence or metastasis was reported. Immunohistochemical analysis showed immunoreactive for estrogen (10/11) and progesterone (8/11) receptor, desmin (6/8), smooth muscle actin (4/10), and vimentin (4/4), S-100 (1/8) and CD34 (1/7). The Ki67 level was less than 5 % in five cases. AAM is a hormone-sensitive, distinct rare mesenchymal neoplasm with high incidence of local recurrence. Surgery is the preferred treatment, with complete resection being an essential prerequisite for minimizing the risk of recurrence.</description><identifier>ISSN: 0301-2115</identifier><identifier>ISSN: 1872-7654</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/j.ejogrb.2024.05.012</identifier><identifier>PMID: 38762952</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Aggressive angiomyxoma ; Hormone therapy ; Mesenchymal neoplasm ; Surgical treatment</subject><ispartof>European journal of obstetrics &amp; gynecology and reproductive biology, 2024-07, Vol.298, p.165-170</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-f8de91028425c52a1c18f71fc8e75faafe422600b0bfc229d331b3e9a45d2013</cites><orcidid>0000-0002-8315-3234</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0301211524002392$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38762952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qu, Hong</creatorcontrib><creatorcontrib>Liu, Na</creatorcontrib><creatorcontrib>Liang, Huamao</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Zhuang, Huiyu</creatorcontrib><creatorcontrib>Li, Hua</creatorcontrib><title>Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases</title><title>European journal of obstetrics &amp; gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>•Aggressive angiomyxoma is a rare mesenchymal myxoid neoplasm in women at reproductive age.•The main treatment is surgery, but local recurrence rate is high.•Careful preoperative evaluation and long-term follow-up are important. Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterized by a high recurrence rate, usually observed in the lower genital tract of women during their reproductive age. Seventeen cases of aggressive angiomyxoma confirmed by pathology from January 2007 to December 2021 in Beijing Chao-yang Hospital were included. We collected clinical data and summarized the clinical and immunohistochemical features. All seventeen included patients were females, aged between 23 and 57 years (mean, 37.7 years; median, 42 years). Fourteen patients were newly diagnosed and three were recurrent. The tumors were located in vulva (58.8 %), vagina (23.5 %), buttock (11.8 %), and cervix (5.9 %). The tumors size were 2 to 15 cm in greatest dimension (mean 8 ± 4.4 cm, median 6 cm). Follow-up data was available for nine patients, which ranged from 25 to 124 months (mean, 82 months; median, 80 months). At the end of follow-up, no other recurrence or metastasis was reported. Immunohistochemical analysis showed immunoreactive for estrogen (10/11) and progesterone (8/11) receptor, desmin (6/8), smooth muscle actin (4/10), and vimentin (4/4), S-100 (1/8) and CD34 (1/7). The Ki67 level was less than 5 % in five cases. AAM is a hormone-sensitive, distinct rare mesenchymal neoplasm with high incidence of local recurrence. Surgery is the preferred treatment, with complete resection being an essential prerequisite for minimizing the risk of recurrence.</description><subject>Aggressive angiomyxoma</subject><subject>Hormone therapy</subject><subject>Mesenchymal neoplasm</subject><subject>Surgical treatment</subject><issn>0301-2115</issn><issn>1872-7654</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gcgevew6STbNrgdBil9QEKSeQzY7KSm73ZrsFvvvTWn16FxmYN53Ph5CrilkFOj0bpXhqlv6KmPA8gxEBpSdkDEtJEvlVOSnZAwcaMooFSNyEcIKYnBenpMRL-SUlYKNyefjcukxBLfFRK-Xrmt3312rk84mFlvdYLLBZutCbNax9G6NQ3uffGDvu7BB0--NoR_q3d5CZWJ0wHBJzqxuAl4d84Qsnp8Ws9d0_v7yNnucp4YL2ae2qLGkwIqcCSOYpoYWVlJrCpTCam0xZ2wKUEFlDWNlzTmtOJY6FzUDyifk9jB247uvAUOvWhcMNo1eYzcExUFIkCLnMkrzg9TEu4NHqzbetdrvFAW156lW6sBT7XkqECryjLab44aharH-M_0CjIKHgwDjm1uHXgXjcG2wdj7SUXXn_t_wA6MMiIg</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Qu, Hong</creator><creator>Liu, Na</creator><creator>Liang, Huamao</creator><creator>Wang, Ying</creator><creator>Zhuang, Huiyu</creator><creator>Li, Hua</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8315-3234</orcidid></search><sort><creationdate>20240701</creationdate><title>Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases</title><author>Qu, Hong ; Liu, Na ; Liang, Huamao ; Wang, Ying ; Zhuang, Huiyu ; Li, Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-f8de91028425c52a1c18f71fc8e75faafe422600b0bfc229d331b3e9a45d2013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aggressive angiomyxoma</topic><topic>Hormone therapy</topic><topic>Mesenchymal neoplasm</topic><topic>Surgical treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qu, Hong</creatorcontrib><creatorcontrib>Liu, Na</creatorcontrib><creatorcontrib>Liang, Huamao</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Zhuang, Huiyu</creatorcontrib><creatorcontrib>Li, Hua</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of obstetrics &amp; gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qu, Hong</au><au>Liu, Na</au><au>Liang, Huamao</au><au>Wang, Ying</au><au>Zhuang, Huiyu</au><au>Li, Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases</atitle><jtitle>European journal of obstetrics &amp; gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>298</volume><spage>165</spage><epage>170</epage><pages>165-170</pages><issn>0301-2115</issn><issn>1872-7654</issn><eissn>1872-7654</eissn><abstract>•Aggressive angiomyxoma is a rare mesenchymal myxoid neoplasm in women at reproductive age.•The main treatment is surgery, but local recurrence rate is high.•Careful preoperative evaluation and long-term follow-up are important. Aggressive angiomyxoma is an uncommon mesenchymal neoplasm characterized by a high recurrence rate, usually observed in the lower genital tract of women during their reproductive age. Seventeen cases of aggressive angiomyxoma confirmed by pathology from January 2007 to December 2021 in Beijing Chao-yang Hospital were included. We collected clinical data and summarized the clinical and immunohistochemical features. All seventeen included patients were females, aged between 23 and 57 years (mean, 37.7 years; median, 42 years). Fourteen patients were newly diagnosed and three were recurrent. The tumors were located in vulva (58.8 %), vagina (23.5 %), buttock (11.8 %), and cervix (5.9 %). The tumors size were 2 to 15 cm in greatest dimension (mean 8 ± 4.4 cm, median 6 cm). Follow-up data was available for nine patients, which ranged from 25 to 124 months (mean, 82 months; median, 80 months). At the end of follow-up, no other recurrence or metastasis was reported. Immunohistochemical analysis showed immunoreactive for estrogen (10/11) and progesterone (8/11) receptor, desmin (6/8), smooth muscle actin (4/10), and vimentin (4/4), S-100 (1/8) and CD34 (1/7). The Ki67 level was less than 5 % in five cases. AAM is a hormone-sensitive, distinct rare mesenchymal neoplasm with high incidence of local recurrence. Surgery is the preferred treatment, with complete resection being an essential prerequisite for minimizing the risk of recurrence.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>38762952</pmid><doi>10.1016/j.ejogrb.2024.05.012</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8315-3234</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0301-2115
ispartof European journal of obstetrics & gynecology and reproductive biology, 2024-07, Vol.298, p.165-170
issn 0301-2115
1872-7654
1872-7654
language eng
recordid cdi_proquest_miscellaneous_3057075437
source Elsevier ScienceDirect Journals
subjects Aggressive angiomyxoma
Hormone therapy
Mesenchymal neoplasm
Surgical treatment
title Aggressive angiomyxoma of female pelvis and perineum: Retrospective study of 17 cases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aggressive%20angiomyxoma%20of%20female%20pelvis%20and%20perineum:%20Retrospective%20study%20of%2017%20cases&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=Qu,%20Hong&rft.date=2024-07-01&rft.volume=298&rft.spage=165&rft.epage=170&rft.pages=165-170&rft.issn=0301-2115&rft.eissn=1872-7654&rft_id=info:doi/10.1016/j.ejogrb.2024.05.012&rft_dat=%3Cproquest_cross%3E3057075437%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3057075437&rft_id=info:pmid/38762952&rft_els_id=S0301211524002392&rfr_iscdi=true